Impact of incubation conditions on bufuralol human clearance predictions: Enzyme lability and nonspecific binding

Drug Metabolism and Disposition

Volumn 32, Issue 3, 2004, Pages 295-304

  Foti, Robert S ^a   Fisher, Michael B ^a,b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFURALOL; CYTOCHROME P450; CYTOCHROME P450 2D6; DIMETHYLANILINE MONOOXYGENASE; ENZYME; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; INCUBATION TIME; LIVER MICROSOME; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING;

ADRENERGIC BETA-ANTAGONISTS; BLOTTING, WESTERN; CYTOCHROME P-450 CYP2D6; ETHANOLAMINES; FREE RADICAL SCAVENGERS; HUMANS; HYDROXYLATION; ISOENZYMES; MICROSOMES, LIVER; NADP; PROTEIN BINDING; REACTIVE OXYGEN SPECIES; RECOMBINANT PROTEINS; TEMPERATURE;

LETHRINIDAE;

EID: 1342323556     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.3.295     Document Type: Article

References (34)

1. Banker MJ, Clark TH, and Williams JA (2002) Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92:967-974.
2. Cashman JR (1999) In vitro metabolism: FMO and related oxygenations, in Handbook of Drug Metabolism (Woolf TF ed) pp 478-479, Marcel Dekker, Inc., New York.
3. Clarke SE (1998) In vitro assessment of human cytochrome P450. Xenobiotica 28:1167-1202.
4. Dayer P, Balant L, Kupfer A, Striberni R, and Leemann T (1985) Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol. Eur J Clin Pharmacol 28:317-320.
5. Dayer P, Gasser R, Gut J, Kronbach T, Robertz G, Eichelbaum M, and Meyer UA (1984) Characterization of a common genetic defect of cytochrome P-450 function (debrisoquinesparteine type polymorphism)-increased Michaelis constant (Km) and loss of stereoselectivity of bufuralol 1′-hydroxylase in poor metabolizers. Biochem Biophys Res Commun 125:374-380.
6. Dayer P, Kronbach, Eichelbaum M and Meyer UA (1987) Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation-characterization of bufuralol 1′-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency. Biochem Pharmacol 36:4145-4152.
7. Ding S, Yao D, Deeni YY, Burchell B, Wolf CR, and Friedberg T (2001) Human NADPH-P450 oxidoreductase modulates the level of cytochrome P450 CYP2D6 holoprotein via haem oxygenase-dependent and -independent pathways. Biochem J 356:613-619.
8. Goasduff T and Cederbaum AI (1999) NADPH-dependent microsomal electron transfer increases degradation of CYP2E1 by the proteasome complex: role of reactive oxygen species. Arch Biochem Biophys 370:258-270.
9. Gram TE and Fouts JR (1966) Time course differences in the metabolism of drugs by hepatic microsomes from rats, rabbits and mice. J Pharmacol Exp Ther 152:363-371.
10. Hiroi T, Chow T, Imaoka S, and Funae Y (2002) Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab Dispos 30:970-976.
11. Houston JB and Carlile DJ (1997) Prediction of hepatic clearance from microsomes, hepatocytes and liver slices. Drug Met Rev 29:981-922.
12. Kalvass JC, Tess DA, Giragossian C, Linhares MC, and Maurer TS (2001) Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data. Drug Metab Dispos 29:1332-1336.
13. Kronbach T, Mathys D, Gut J, Catin T, and Meyer UA (1987) High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 162:24-32.
14. Madani S, Paine MF, Lewis L, Thummel KE, and Shen DD (1999) Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res (NY) 16:1199-1205.
15. Mankowski DC (1999) The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6. Drug Metab Dispos 27:1024-1028.
16. Marcucci KA, Pearce RE, Crespi C, Steimel DT, Leeder JS, and Gaedigk A (2002) Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metab Dispos 30:595-601.
17. Margolis JM and Obach RS (2003) Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 31:606-611.
18. McGinnity DF, Parker AJ, Soars M, and Riley RJ (2000) Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Met Dispos 28:1327-1344.
19. McGinnity DF and Riley RJ (2001) Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochem Soc Trans 29(Pt 2):135-139.
20. McLure JA, Miners JO, and Birkett DJ (2000) Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 49:453-461.
21. Mimura M, Yamazaki H, Sugahara C, Hiroi T, Funae Y, and Shimada T (1994) Differential roles of cytochromes P450 2D1, 2C11 and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes. Biochem Pharmacol 47:1957-1963.
22. Minder EI, Meier PJ, Müller HK, Minder C, and Meyer UA (1983) Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation. Eur J Clin Investig 14:184-189.
23. Nakamura K, Ariyoshi N, Yokoi T, Ohgiya S, Chida M, Nagashima K, Inoue K, Kodama T, Shimada N, and Kamataki T (2002) CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. Biochem Biophys Res Commun 293:969-973.
24. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, and Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316-1324.
25. Obach RS (1997) Nonspecific binding to microsomes: impact of scale-up on in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine and propranolol. Drug Metab Dispos 25:1359-1369.
26. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
27. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
28. Prueksaritanont T, Dwyer LM, and Cribb AE (1995) (+)-Bufuralol l′-hydroxylation activity in human and rhesus monkey intestine and liver. Biochem Pharmacol 50:1521-1525.
29. Rodrigues AD (1997) Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective. Pharm Res (NY) 14:1504-1510.
30. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
31. Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.
32. Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BJ, Rettie AE, and Cashman JR (1993) In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev 25:453-484.
33. Yamazaki H, Guo Z, Persmark M, Mimura M, Inoue K, Guengerich FP, and Shimada T (1994) Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol Pharmacol 46:568-577.
34. Yu A, Kneller BM, Rettie AE, and Haining RL (2002) Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10 and 2D6.17 allelic isoforms. J Pharmacol Exp Ther 303:1291-1300.